Yun Fan Liaw

Summary

Affiliation: Liver Research Unit
Country: Taiwan

Publications

  1. ncbi request reprint Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    J Gastroenterol Hepatol 17:S333-7. 2002
  2. ncbi request reprint Asian-Pacific consensus statement on the management of chronic hepatitis B: an update
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University, Taipei, Taiwan
    J Gastroenterol Hepatol 18:239-45. 2003
  3. ncbi request reprint Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy
    Yun Fan Liaw
    Liver Research Unit, Medical College, Chang Gung University, Taipei, Taiwan
    J Gastroenterol Hepatol 18:246-52. 2003
  4. doi request reprint Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taipei, 105, Taiwan
    Dig Dis Sci 55:2727-34. 2010
  5. ncbi request reprint Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University and Memorial Hospital, 199, Tung Hwa North Road, Taipei, Taiwan
    J Gastroenterol Hepatol 19:S73-5. 2004
  6. ncbi request reprint Results of lamivudine trials in Asia
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and Chiang Gung University, 199 Tung Hwa North Road, Taipei, Taiwan
    J Hepatol 39:S111-5. 2003
  7. ncbi request reprint Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University and Memorial Hospital, Taipei, Taiwan
    J Gastroenterol Hepatol 19:S73-5. 2004
  8. ncbi request reprint Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 199 Tung Hwa North Road, Taipei, Taiwan
    J Hepatol 51:403-10. 2009
  9. ncbi request reprint No benefit to continue lamivudine therapy after emergence of YMDD mutations
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    Antivir Ther 9:257-62. 2004
  10. ncbi request reprint Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    Liver Int 25:472-89. 2005

Detail Information

Publications98

  1. ncbi request reprint Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    J Gastroenterol Hepatol 17:S333-7. 2002
    ....
  2. ncbi request reprint Asian-Pacific consensus statement on the management of chronic hepatitis B: an update
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University, Taipei, Taiwan
    J Gastroenterol Hepatol 18:239-45. 2003
  3. ncbi request reprint Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy
    Yun Fan Liaw
    Liver Research Unit, Medical College, Chang Gung University, Taipei, Taiwan
    J Gastroenterol Hepatol 18:246-52. 2003
    ..In conclusion, a better understanding of the pathogenetic mechanisms and natural course of hepatitis flares, wiser selection of patients and the timing of drug therapy are crucial to achieve better treatment results...
  4. doi request reprint Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taipei, 105, Taiwan
    Dig Dis Sci 55:2727-34. 2010
    ..The importance of HBeAg seroconversion is underscored by current CHB treatment guidelines that recommend limiting the duration of antiviral therapy in HBeAg-positive patients who achieve seroconversion...
  5. ncbi request reprint Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University and Memorial Hospital, 199, Tung Hwa North Road, Taipei, Taiwan
    J Gastroenterol Hepatol 19:S73-5. 2004
    ..Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising...
  6. ncbi request reprint Results of lamivudine trials in Asia
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and Chiang Gung University, 199 Tung Hwa North Road, Taipei, Taiwan
    J Hepatol 39:S111-5. 2003
    ..The development of new strategies, including selection of patient and timing of therapy, and new drugs are needed to further improve the therapeutic efficacy...
  7. ncbi request reprint Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University and Memorial Hospital, Taipei, Taiwan
    J Gastroenterol Hepatol 19:S73-5. 2004
    ..Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising...
  8. ncbi request reprint Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 199 Tung Hwa North Road, Taipei, Taiwan
    J Hepatol 51:403-10. 2009
    ..Cost-cutting measures and international support are essential to improve the difficult situation in this part of the world...
  9. ncbi request reprint No benefit to continue lamivudine therapy after emergence of YMDD mutations
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    Antivir Ther 9:257-62. 2004
    ..In addition, experiments have shown that the defective replication competency of rt M 204 I/V restores upon addition of lamivudine...
  10. ncbi request reprint Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    Liver Int 25:472-89. 2005
    ..A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update...
  11. ncbi request reprint Lamivudine for patients with chronic hepatitis B and advanced liver disease
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    N Engl J Med 351:1521-31. 2004
    ..The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown...
  12. ncbi request reprint Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion
    C M Chu
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    J Viral Hepat 14:147-52. 2007
    ..Antiviral or immunomodulatory therapy should be considered seriously for these patients...
  13. ncbi request reprint Management of patients with chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University Memorial Hospital, 199 Tung Hwa North Road, Taipei, Taiwan
    J Gastroenterol Hepatol 17:406-8. 2002
    ..Further development of new drugs and new strategies, such as combination or sequential therapy, may help to better achieve the goals of treatment for chronic hepatitis B in the new century...
  14. doi request reprint 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Gastroenterology 136:486-95. 2009
    ..The GLOBE trial has compared the efficacy and safety of telbivudine versus lamivudine treatment over 2 years in patients with chronic hepatitis B...
  15. ncbi request reprint Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University, Taipei, Taiwan
    Antivir Ther 11:669-79. 2006
    ..The ability to achieve a high rate of sustained or maintained HBV suppression with a low risk of drug resistance would be the ultimate goal in the treatment of chronic HBV infection...
  16. doi request reprint Natural history of chronic hepatitis B virus infection and long-term outcome under treatment
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Liver Int 29:100-7. 2009
    ..The treatment outcomes are still far from satisfactory. The development of safe and affordable anti-HBV agents/strategies is needed to further improve outcomes...
  17. ncbi request reprint Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis
    Y F Liaw
    Liver Research Unit, Lin Kou, Taiwan
    J Viral Hepat 13:250-5. 2006
    ..To stop LAM and switch to ADV in patients with breakthrough is a reasonably safe and cost-effective approach...
  18. ncbi request reprint The current management of HBV drug resistance
    Yun Fan Liaw
    Liner Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    J Clin Virol 34:S143-6. 2005
    ..The impact of adefovir resistance is less clear but is responsive to lamivudine therapy. In conclusion, monitoring of viral breakthrough to start effective intervention is mandatory during direct antiviral therapy...
  19. ncbi request reprint On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Antivir Ther 14:13-22. 2009
    ..In addition, studies are needed to decide whether switching to or adding on a second drug, and with which drug, is the most cost-effective strategy...
  20. doi request reprint Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death
    Jin De Chen
    Department of Internal Medicine, Bei Hu Branch, National Taiwan University Hospital, Taipei, Taiwan
    Gastroenterology 138:1747-54. 2010
    ..The risk and the predictors of liver disease progression in carriers of inactive hepatitis B virus (HBV) are unclear...
  21. doi request reprint Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success
    Rong Nan Chien
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Best Pract Res Clin Gastroenterol 22:1081-92. 2008
    ..However, drug resistance is a serious risk on prolonged nucleos(t)ide analogue therapy, and this poses a critical challenge. Prevention and proper management of drug resistance are crucial to ensure long-term success...
  22. ncbi request reprint Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan
    Ming Whei Yu
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    Int J Epidemiol 31:1008-15. 2002
    ....
  23. ncbi request reprint Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men
    Ming Whei Yu
    Department of Public Health, Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    J Natl Cancer Inst 97:265-72. 2005
    ..Although chronic infection with hepatitis B virus (HBV) has been established as a cause of hepatocellular carcinoma (HCC), the roles of viral load and HBV genotype remain unclear...
  24. doi request reprint Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age
    Dar In Tai
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    Am J Gastroenterol 105:1102-9. 2010
    ..Their relative roles in the decline of HBsAg prevalence with increasing age are unknown...
  25. ncbi request reprint Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen
    Chau Ting Yeh
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University School of Medicine, Taipei, Taiwan
    J Gastroenterol Hepatol 18:1129-38. 2003
    ..The aim of the present study was to investigate whether spontaneous seroclearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B could be attributed to the presence of pre-S/S gene mutations...
  26. ncbi request reprint Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma
    Chien Hung Chen
    Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, ROC
    J Hepatol 40:653-9. 2004
    ..The route of HBV transmission differs between the children and siblings of patients with HCC. This study examined the differences in HBV carrier rates and HCC-related mortality between two generations in HCC families...
  27. ncbi request reprint Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma
    Ming Whei Yu
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    J Natl Cancer Inst 95:1485-8. 2003
    ..07, 95% confidence interval = 1.67 to 38.93) than for those with the Arg/Arg genotype. Thus, GST status appears to affect the risk of HCC associated with this XRCC1 polymorphism...
  28. doi request reprint Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients
    Wen Juei Jeng
    Liver Research Unit, Linkou Medical Center, Chang Gung Memorial Hospital, Taipei, Taiwan College of Medicine, Chang Gung University, Taipei, Taiwan
    Hepatology 58:1888-96. 2013
    ..027). For the latter, consolidation therapy >64 weeks reduced the relapse rate to 33.3% in patients without cirrhosis...
  29. ncbi request reprint Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B
    Ming Ling Chang
    Liver Research Unit, Chang Gung Memorial Hospital and University, 199, Tung Hwa North Road, Taipei, Taiwan
    J Hepatol 43:72-7. 2005
    ..The aim was to evaluate the impact of viral factors, host factors, host-viral interaction and drug factor on the emergence of rtM204 I/V...
  30. ncbi request reprint Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance
    Chao Wei Hsu
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    Gastroenterology 132:543-50. 2007
    ..It is generally believed to be a benevolent sign, implicating clearance of viremia. The aim of this study is to examine the authenticity of this dogma...
  31. ncbi request reprint Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk
    Ming Whei Yu
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    Hepatology 38:1393-400. 2003
    ..0053). In conclusion, increased exposure to estrogen during adulthood may provide a protective effect against HCC. Nevertheless, an early menarche, which results in early estrogen exposure, does not confer protection for HBsAg carriers...
  32. doi request reprint Influences of tobacco and alcohol use on hepatocellular carcinoma survival
    Wei Liang Shih
    Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
    Int J Cancer 131:2612-21. 2012
    ..Quitting smoking or drinking alcohol could reduce the excess risk, but only after a long interval of cessation...
  33. ncbi request reprint Determinants for sustained HBeAg response to lamivudine therapy
    Rong Nan Chien
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    Hepatology 38:1267-73. 2003
    ..In conclusion, HBV genotype, age, and additional treatment are the major determinants for the sustained HBeAg response to lamivudine therapy...
  34. ncbi request reprint Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
    Shi Ming Lin
    Liver Research Unit, Chang Gung University and Chang Gung Memorial Hospital, Taipei, Taiwan
    J Hepatol 46:45-52. 2007
    ..The long-term outcomes of interferon-alpha (IFN-alpha) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue...
  35. ncbi request reprint Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
    Yao Shih Hsu
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan
    Hepatology 35:1522-7. 2002
    ..005). In conclusion, the results suggest that spontaneous HBeAg seroconversion confers favorable long-term outcomes. However, active hepatitis still may develop and lead to cirrhosis and HCC...
  36. doi request reprint Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon gamma signalling pathway
    Hsuan Hao Huang
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Zhongzheng District, Taipei, Taiwan
    Gut 60:99-107. 2011
    ....
  37. pmc Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study
    Wei Liang Shih
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    Eur J Hum Genet 17:1250-9. 2009
    ..These results implicate PAPSS1 as a candidate HCC-susceptibility gene in hepatitis B carriers...
  38. doi request reprint Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma
    Chia Ming Chu
    Department of Gastroenterology and Hepatology, Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 199 Tung Hwa North Road, Taipei 10591, Taiwan
    Dig Dis Sci 57:232-8. 2012
    ..A case-control study including patients with early HCC and HBsAg carriers who are presumed to be at the minimal potential of HCC as controls might better identify factors significantly associated with HCC development...
  39. ncbi request reprint Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Clin Gastroenterol Hepatol 8:535-40. 2010
    ..We investigated HBV DNA levels in inactive carriers and identified factors that correlated with this state among anti-HBe-positive carriers with HBV DNA levels of 10(4) copies/mL or greater (5.26 copies/mL = 1 IU/mL)...
  40. ncbi request reprint Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    Gastroenterology 126:1024-9. 2004
    ..The natural course following acute hepatitis C virus (HCV) superinfection has not been well studied. The aim of this study was to investigate the impact of acute HCV superinfection...
  41. doi request reprint Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression
    Feng Yu Sung
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    Gastroenterology 137:1687-97. 2009
    ..We assessed the influence of genetic variants in the hepatitis B virus (HBV) core, which is a principal immunologic target, on the progression to hepatocellular carcinoma (HCC) in a cohort of 4841 male HBV carriers followed up for 16 years...
  42. ncbi request reprint Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection
    Yi Cheng Chen
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    Gastroenterology 123:1084-9. 2002
    ..The aim of this study was to clarify the controversy on long-term prognosis following spontaneous HBsAg seroclearance using a large series of patients...
  43. ncbi request reprint Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at bas
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University Taipei, 199, Tung Hwa North Road, Taipei 105, Taiwan, ROC
    J Hepatol 43:411-7. 2005
    ..Longitudinal studies on the relationship between hepatitis B virus (HBV) genotypes and reactivation of hepatitis B and progression to cirrhosis were very rare...
  44. ncbi request reprint Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan
    Rong Nan Chien
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Keelung, Taiwan
    Antivir Ther 11:947-52. 2006
    ..It is concluded that in HBeAg-negative chronic hepatitis B patients with ALT levels above 5x ULN, a 6-12 month course of lamivudine therapy may achieve sustained an off-treatment response in approximately one-third of patients...
  45. ncbi request reprint Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Dig Liver Dis 42:S293-7. 2010
    ..However, the treatment outcomes are still far from satisfactory. The development of safe and affordable anti-HBV agents/strategies is needed to further improve outcomes...
  46. ncbi request reprint Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B
    Wen Juei Jeng
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Clin Gastroenterol Hepatol 8:541-5. 2010
    ..It is important to identify factors that predict the development of hepatic decompensation during exacerbation so that antiviral therapy can be initiated immediately...
  47. ncbi request reprint Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infection
    Dar In Tai
    Liver Research Unit, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC
    J Gastroenterol Hepatol 17:682-9. 2002
    ..We determine the number of fatalities in relatives of HCC patients during an 8-year period to understand the risk and cause of HCC in relatives of patients with HCC...
  48. ncbi request reprint The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B
    Rong Nan Chien
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, 199 Tung Hwa North Road, Taipei, 105 Taiwan
    J Hepatol 38:322-7. 2003
    ..Severe acute exacerbation (AE) of chronic hepatitis B (CHB) can lead to hepatic decompensation and death. The aim of this study was to investigate the effect of lamivudine therapy in hepatic decompensation during such AEs...
  49. ncbi request reprint Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors
    Shi Ming Lin
    Liver Research Unit, Chang Gung Memorial Hospitaland Chang Gung University, 199 Tung Hwa North Road, Taipei, Taiwan
    Cancer 100:376-82. 2004
    ..Hepatocellular carcinoma (HCC) recurrence after ablation therapy for primary tumors is common...
  50. doi request reprint Immunopathology on hepatocyte expression of HBV surface, core, and x antigens in chronic hepatitis B: clinical and virological correlation
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 199 Tung Hwa North Road, Taipei 10591, Taiwan
    Dig Dis Sci 55:446-51. 2010
    ..Hepatocyte expression of HBV surface, core, and x antigens (HBsAg, HBcAg and HBxAg), semi-quantitated by immunopathology, were correlated with clinical and virological data in 80 patients with chronic hepatitis B...
  51. doi request reprint Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Hepatology 54:91-100. 2011
    ..Biochemical and clinical benefits were also demonstrated. Entecavir was well tolerated, and early mortality rates were consistent with rates observed in similar populations treated with lamivudine...
  52. pmc Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma
    Hwai I Yang
    Genomics Research Center, Academia Sinica and Graduate Institute of Epidemiology, National Taiwan University, Taipei, Taiwan
    J Natl Cancer Inst 100:1134-43. 2008
    ..We examined the HCC risk associated with HBV genotypes and common variants in the precore and basal core promoter (BCP) regions...
  53. ncbi request reprint Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Gastroenterology 133:1458-65. 2007
    ..Predictors of reactivation of hepatitis B following hepatitis B e antigen (HBeAg) seroconversion in chronic hepatitis B have rarely been reported before and deserve further study...
  54. ncbi request reprint Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Am J Gastroenterol 104:1693-9. 2009
    ....
  55. ncbi request reprint Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital, and Chang Gung University, Taipei, Taiwan
    Am J Med 116:829-34. 2004
    ..Follow-up of patients beginning at the early phase of infection might provide data with less referral bias than in previous studies...
  56. pmc Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan
    J Clin Microbiol 40:16-21. 2002
    ..Precore mutant ratios tended to correlate with ALT levels and anti-HBe seroconversion, but high precore mutant ratios were associated with persistent hepatitis after anti-HBe seroconversion and increased risk of cirrhosis...
  57. ncbi request reprint Short-term lamivudine therapy in patients with chronic hepatitis B
    Rong Nan Chien
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan
    Intervirology 46:362-6. 2003
    ..However, the relapse rate was high (60% during 1-year follow-up). Further study is needed to establish how to improve a sustained HBeAg response...
  58. doi request reprint Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression
    Chau Ting Yeh
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    J Clin Virol 45:114-8. 2009
    ..The outcome of patients following this therapeutic guideline has not been clearly investigated...
  59. doi request reprint Impact of therapy on the outcome of chronic hepatitis B
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Liver Int 33:111-5. 2013
    ..However, treatment outcomes are still far from satisfactory. The development of more effective and safe but affordable anti-HBV agents/strategies is needed to further improve outcomes...
  60. ncbi request reprint HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University, Taipei, Taiwan
    Hepatology 45:1187-92. 2007
    ..In multivariate analysis, the probability of HBsAg seroclearance correlated positively with age at entry (P<0.0001) and sustained remission of hepatitis (P<0.0001) and marginally significantly with male sex (P=0.053)...
  61. ncbi request reprint Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy
    Ming Wei Lai
    Liver Research Unit, Chang Gung Medical Center, Taipei, Taiwan
    Antivir Ther 14:249-61. 2009
    ..The significance of such mutations in hepatocarcinogenesis remains elusive. Here, we aimed to understand the oncogenicity of HBV pre-S/S nonsense mutations identified in patients with HCC that developed after lamivudine therapy...
  62. ncbi request reprint Hepatitis C virus infection facilitates gallstone formation
    Te Sheng Chang
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    J Gastroenterol Hepatol 20:1416-21. 2005
    ..The purpose of the present study was to examine the relationship between biliary diseases and hepatitis C virus infection...
  63. ncbi request reprint Hepatitis B virus-related cirrhosis: natural history and treatment
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University, Taipei, Taiwan
    Semin Liver Dis 26:142-52. 2006
    ..Adefovir or entecavir is preferred in patients with decompensated cirrhosis who require long duration of treatment, due to the lower rate of development of resistance...
  64. ncbi request reprint Comparative studies on expression of alpha-smooth muscle actin in hepatic stellate cells in chronic hepatitis B and C
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taipei, Taiwan
    Dig Dis Sci 53:1364-9. 2008
    ..We performed a comparative study on the expression of alpha-smooth muscle actin (alpha-SMA) in hepatic stellate cells (HSCs), a marker of HSC activation, in patients with chronic hepatitis B and hepatitis C...
  65. ncbi request reprint Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University, Taipei, Taiwan
    Semin Liver Dis 25:40-7. 2005
    ..For HCC not prevented by these measures, surveillance using ultrasonography and serum alpha-fetoprotein assay every 3 to 6 months is able to detect HCC at an earlier stage and allows curative therapy with survival benefit...
  66. doi request reprint Hepatitis B virus infection
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Lancet 373:582-92. 2009
    ..However, hepatitis B virus is rarely eliminated, and drug resistance is a major drawback during long term therapy. The development of new drugs and strategies is needed to improve treatment outcomes...
  67. doi request reprint Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection
    Yi Cheng Chen
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Clin Gastroenterol Hepatol 10:297-302. 2012
    ..Serum levels of hepatitis B surface antigen (HBsAg) decrease gradually during chronic hepatitis B virus infection. We investigated the association between levels of HBsAg and HBsAg seroclearance...
  68. doi request reprint Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers
    Chia Ming Chu
    Liver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Clin Infect Dis 54:88-90. 2012
    ..The frequency of HBV viremia was significantly (P = .002) lower in patients with anti-HBsAg seroconversion (6 of 69 [8.7%]) than in those without seroconversion (15 of 49 [30.6%])...
  69. doi request reprint Impact of hepatitis B therapy on the long-term outcome of liver disease
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Liver Int 31:117-21. 2011
    ..However, the treatment outcomes still need to be improved, and more effective, safe and affordable anti-HBV agents/strategies are needed...
  70. doi request reprint Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B
    Yi Cheng Chen
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Hepatology 51:435-44. 2010
    ..7% [P < 0.0001], 42.9% [P <0.0001], and 7.7% [P = 0.29], respectively). The hazard ratio of HBeAg-negative hepatitis, cirrhosis, and HCC was 2.95, 17.6, and 5.22, respectively, in group C compared with group A...
  71. doi request reprint Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Hepatology 53:62-72. 2011
    ..Hepatitis B e antigen (HBeAg) loss/seroconversion occurred in 21%/21% (TDF), 27%/13% (FTC/TDF), and 0%/0% (ETV). Child-Turcotte-Pugh and Modification for End-stage Liver Disease scores improved in all groups...
  72. doi request reprint Hepatitis B surface antigen seroclearance during chronic HBV infection
    Chia Ming Chu
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Antivir Ther 15:133-43. 2010
    ..Studies to assess the effects of antiviral therapy, and in particular interferon treatment, are also discussed together with virological, biochemical and histological profiles following HBsAg seroclearance and the long-term outcomes...
  73. ncbi request reprint Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma
    Cheng Yuan Peng
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Tao Yuan, Taiwan
    Anticancer Res 22:1265-71. 2002
    ..results suggest that p14(ARF), p16(INK4a) and p53 are differentially disrupted through distinct molecular mechanisms at different stages in HCC and that p14(ARF) and p53 appear to function in the same tumor suppression pathway in HCC..
  74. ncbi request reprint A method to increase tetramer staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment
    Sun Lung Tsai
    Department of Medical Research, Liver Research Unit, Chi Mei Foundation Medical Center, Tainan, Taiwan
    J Immunol Methods 285:71-87. 2004
    ..Significantly, it achieves high frequencies of tetramer staining of CD8+ T cells allowing the data of different individuals to be easily compared and sequentially evaluated. The mechanisms involved in this method are discussed...
  75. doi request reprint Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time
    Dar In Tai
    Liver Research Unit, Chang Gung Memorial Hospital, Chung Gung University College of Medicine, Taipei, Taiwan
    Hepatology 49:1859-67. 2009
    ....
  76. ncbi request reprint Antisense overexpression of BMAL2 enhances cell proliferation
    Chau Ting Yeh
    Liver Research Unit, Chang Gung Memorial Hospital, 199 Tung Hwa North Road, Taipei, Taiwan
    Oncogene 22:5306-14. 2003
    ..In conclusion, by combining three different methods, we have obtained a panel of frequently down regulated genes in HCC, including BMAL2. Antisense overexpression of BMAL2 enhances cell proliferation...
  77. doi request reprint The natural history of chronic HBV infection and geographical differences
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Antivir Ther 15:25-33. 2010
    ....
  78. ncbi request reprint Thymalfasin for the treatment of chronic hepatitis B
    Rong Nan Chien
    Liver Research Unit, Chang Gung Memorial Hospital, 199 Tung Hwa North Road, Taipei, Taiwan
    Expert Rev Anti Infect Ther 2:9-16. 2004
    ..In terms of the mechanisms of action, a combination of Talpha1 and nucleoside or nucleotide analogs is a logical approach in the control of chronic HBV infection and a randomized control study is ongoing...
  79. doi request reprint Gene gun bombardment with DNA-coated gold particles is a potential alternative to hydrodynamics-based transfection for delivering genes into superficial hepatocytes
    Ming Ling Chang
    Liver Research Center and Department of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    Hum Gene Ther 19:391-5. 2008
    ....
  80. ncbi request reprint Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    J Gastroenterol 37:65-8. 2002
    ..The basic mechanisms that regulate the viral interactions largely remain to be investigated...
  81. ncbi request reprint Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management
    Anna S Lok
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 46:254-65. 2007
    ..Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy...
  82. ncbi request reprint Chronic hepatitis B guidelines: east versus west
    Yun Fan Liaw
    Hepatology 35:979-81; author reply 981-2. 2002
  83. ncbi request reprint Viral load in hepatitis B e antigen-negative carriers with normal aminotransferase level
    Yun Fan Liaw
    Hepatology 46:947; author reply 947-9. 2007
  84. ncbi request reprint A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan
    Ming Lung Yu
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    Antivir Ther 11:985-94. 2006
    ....
  85. ncbi request reprint Telbivudine versus lamivudine in patients with chronic hepatitis B
    Ching Lung Lai
    University Department of Medicine, Queen Mary Hospital, Hong Kong, China
    N Engl J Med 357:2576-88. 2007
    ..Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B...
  86. ncbi request reprint Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
    Robert P Perrillo
    Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Hepatology 36:186-94. 2002
    ..Asians and Caucasians had similar rates of response to lamivudine at comparable ALT levels...
  87. doi request reprint HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27599 7584, USA
    Hepatology 47:428-34. 2008
    ..Late responders to peginterferon alfa-2a could also be differentiated from nonresponders by continued decrease in HBeAg values, which were not evident by changes in HBV DNA...
  88. doi request reprint Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks
    Morris Sherman
    Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    Hepatology 48:99-108. 2008
    ..The safety profile of entecavir in the second year of therapy was consistent with that reported during year 1...
  89. ncbi request reprint Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
    Morris Sherman
    Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    Gastroenterology 130:2039-49. 2006
    ..In preclinical and phase II studies, entecavir demonstrated potent antiviral activity against lamivudine-resistant HBV...
  90. ncbi request reprint Hepatitis B e antigen and the risk of hepatocellular carcinoma
    Hwai I Yang
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei
    N Engl J Med 347:168-74. 2002
    ..We conducted a prospective study to determine the relation between positivity for hepatitis B surface antigen (HBsAg) and HBeAg and the development of hepatocellular carcinoma...
  91. ncbi request reprint Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?
    Yun Fan Liaw
    Hepatology 45:266-8. 2007
  92. ncbi request reprint Chronic hepatitis B: a critical appraisal of current approaches to therapy
    Robert P Perrillo
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Clin Gastroenterol Hepatol 4:233-48. 2006
    ..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...
  93. ncbi request reprint Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma
    Chun Chieh Chen
    Department of Family Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan
    Int J Epidemiol 34:1310-8. 2005
    ..We investigated the mechanisms underlying the inflammatory hepatocarcinogenesis by examining whether genetic variations in cytokines, antioxidant enzymes, and DNA repair genes affect the HCC risk...
  94. ncbi request reprint Spontaneous HBsAg seroclearance confers excellent prognosis except in patients with cirrhosis
    Yi Cheng Chen
    Hepatology 40:501; author reply 501-2. 2004
  95. ncbi request reprint Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women
    Ming Whei Yu
    Department of Public Health and Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, No 1 Jen Ai Road, Section 1, Room 1550, Taipei 100, Taiwan
    Hepatology 36:156-63. 2002
    ..No such relationship was detected among women without the family history. In conclusion, our observations suggest that the AR-CAG alleles may contribute to HCC predisposition among women through a mechanism different from that for men...
  96. ncbi request reprint A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy
    Ming Lung Yu
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    Hepatology 44:1086-97. 2006
    ..Nevertheless, the data needs further validation, particularly since the predictive accuracy for patients with cirrhosis is low...
  97. ncbi request reprint Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications
    Sun Lung Tsai
    Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan
    J Biomed Sci 10:120-35. 2003
    ..In conclusion, activation of Th1 immunity accompanied by enhancement of CTL activity during therapy is a common immune mechanism for successfully treating hepatitis B and C, and therefore may have important therapeutic implications...